MDM2 as a predictor of prostate carcinoma outcome

摘要: BACKGROUND The MDM2 oncoprotein promotes p53 degradation via ubiquitin, establishing negative feedback control of and consequently affecting cell cycle arrest apoptosis. The authors evaluated the association between expression local failure, distant metastasis (DM), cause-specific mortality, overall mortality in men treated Radiation Therapy Oncology Group 8610 with radiotherapy, or without androgen deprivation. METHODS Of 456 eligible analyzable patients (parent cohort), adequate archival diagnostic tissue specimens from 108 were available for analysis (MDM2 cohort). Cox proportional hazards multivariate (MVA) was used to determine relation endpoints. overexpression manually classified as > 5% nuclear staining. An image system also quantify proportion tumor nuclei staining (ACIS index) intensity. RESULTS Overexpression by manual counts seen 44% (n = 47) patients. In count analysis, there no significant outcome. ACIS index, using a cutoff point defined median value, ≤ 3% versus 3%, related 5-year DM rates univariate analyses (32.6% vs. 45.8%; P 0.057) MVA (P 0.06). intensity not significant. CONCLUSIONS MDM2 quantified weakly associated DM. cohort examined relatively small larger patient numbers, may emerge more covariate. Cancer 2005. © 2005 American Society.